Immune checkpoint blockade has become a promising therapeutic approach to reverse
immune cell exhaustion. Coinhibitory CD96 and T‐cell immunoglobulin and ITIM domain …

CD96 is a novel target for cancer immunotherapy shown to regulate NK cell effector function
and metastasis. Here, we demonstrated that blocking CD96 suppressed primary tumor …

CD96 has recently been shown as a negative regulator of mouse natural killer (NK)–cell
activity, with Cd96−/− mice displaying hyperresponsive NK cells upon immune challenge. In …

The recent discovery of immune checkpoint inhibitors is a significant milestone in cancer
immunotherapy research. However, some patients with primary or adaptive drug resistance …

The introduction of immune checkpoint inhibitors in cancer treatment highlights the negative
regulation of anti-tumor immunity, such as effector T-cell exhaustion in the tumor …

We investigated the in vivo role of CD69 by analyzing the susceptibility of CD69−/− mice to
tumors. CD69−/− mice challenged with MHC class I− tumors (RMA-S and RM-1) showed …

Background & Aims The CD47–signal regulatory protein α (SIRPα) axis inhibits dendritic cell
(DC) phagocytosis and contributes to immune evasion. However, the behaviour of DCs and …

CD155/T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a novel type of immune
checkpoint. CD155 is an adhesion molecule that is upregulated during tumor progression …

Background CD161, encoded by killer cell lectin-like receptor B1 gene, is a newly reported
candidate inhibitor of tumour-infiltrating T cells. Antibody-mediated CD161 blockade …

While therapies targeting the co‐inhibitory or immune checkpoint receptors PD‐1 and CTLA‐
4 have shown remarkable success in many cancers, not all patients benefit from these …